2024-10-20 - Analysis Report
## Gilead Sciences Inc (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences Inc is a biopharmaceutical company that researches, develops, and commercializes medicines for various life-threatening diseases. 

**1. Performance Comparison:**

* **Cumulative Return:** GILD: -10.4%, VOO: 137.88%
* **Performance Gap:** GILD has significantly underperformed VOO, with a cumulative return difference of -148.28%.
* **Relative Divergence:** This indicates GILD is currently at the 4.8th percentile of its historical performance relative to VOO. 

**2. Recent Price Movement:**

* **Closing Price:** $86.72
* **5-Day Moving Average:** $86.34
* **20-Day Moving Average:** $84.79
* **60-Day Moving Average:** $80.16

The recent price movement suggests a slight upward trend with the current price above all moving averages.

**3. Technical Indicators:**

* **RSI:** 68.0 (Overbought territory)
* **PPO:** -0.04 (Weak momentum)
* **Delta_Previous_Relative_Divergence:** -1.63 (Short-term bearish)
* **Expected_Return:** 0.0% (Expected long-term return relative to S&P 500)

The RSI suggests that the stock is currently overbought, while the PPO indicates weak momentum. The Delta_Previous_Relative_Divergence suggests a short-term bearish trend.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report for Q2 2024 showed EPS of $1.29, beating analysts' estimates of $1.19. Revenue also surpassed expectations, coming in at $6.95 billion compared to the projected $6.86 billion.

**5. News and Recent Issues:**

* **Recent Market Outlook:** Gilead Sciences' stock price has been relatively flat in recent months, with investors focused on the company's long-term growth prospects in the biopharmaceutical industry. 
* **Analyst Opinions:** Many analysts remain bullish on Gilead Sciences, citing its strong pipeline of new drugs and its position as a leader in the HIV and hepatitis C markets. However, some analysts express concerns about the company's dependence on a few key products and the potential for generic competition.
* **Performance Highlights:** Gilead Sciences continues to invest heavily in research and development, with several promising new drugs in clinical trials. The company is also focusing on expanding its presence in emerging markets.

**6. Conclusion:**

Gilead Sciences has significantly underperformed the market in recent years, but recent earnings results suggest a potential rebound. The company's strong product pipeline and focus on R&D offer long-term growth potential. However, investors should be aware of the risks associated with its dependence on a few key products and the potential for generic competition.  

**7. Overall Analysis:**

Gilead Sciences Inc is a biopharmaceutical company that has faced challenges in recent years but remains a leader in its industry. The company's strong earnings performance in the most recent quarter, coupled with its robust pipeline, suggests a potential for future growth. However, investors should be mindful of the stock's historical underperformance and the potential risks associated with generic competition. 
